Piramal Pharma Limited

What does Piramal Pharma own?
Piramal Pharma owns three business divisions: Piramal Pharma Solutions (CDMO services), Piramal Critical Care (hospital generics and inhalational anesthetics), and the Consumer Healthcare Division (OTC products in India). Its consumer brands include Lacto Calamine, i-pill, Saridon, Littles, and Naturolax. The company operates 17 manufacturing facilities across India, the United States, the United Kingdom, Canada, and Germany.

Is Piramal Pharma publicly traded?
Yes, Piramal Pharma is listed on the National Stock Exchange of India (NSE: PPLPHARMA) and the Bombay Stock Exchange (BSE: 543635). The company was demerged from Piramal Enterprises Limited and listed as a separate entity on October 19, 2022. Shares are held by institutional investors, the Piramal family, Carlyle Group, and public shareholders.

Who founded Piramal Pharma?
Piramal Pharma's origins trace to 1988, when the Piramal Group, led by Ajay Piramal, acquired Nicholas Laboratories India Limited. This acquisition marked the group's entry into the pharmaceutical industry. The modern Piramal Pharma Limited was created through a demerger from Piramal Enterprises in 2022. Ajay Piramal serves as Chairman, and his daughter Nandini Piramal serves as Executive Director.

Where is Piramal Pharma headquartered?
Piramal Pharma is headquartered in Mumbai, Maharashtra, India. The company's corporate offices are in the Piramal Tower in Lower Parel, Mumbai. The company was incorporated in India and is subject to Indian corporate law and regulations.

How many brands does Piramal Pharma own?
Piramal Pharma owns three business division brands (Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare) and approximately 7 consumer healthcare product brands sold in India. The consumer brands include Lacto Calamine, i-pill, Saridon, Littles, and Naturolax. See the full brand index for the complete list.

Who owns Piramal Pharma?
Piramal Pharma is controlled by the Piramal Group, led by Ajay Piramal and his family, which holds the majority of shares through Piramal Enterprises Limited and other group entities. The Carlyle Group holds a significant minority stake of approximately 15%, acquired through a $490 million investment in 2020. The remainder is held by institutional and public shareholders.

What is Piramal Pharma's revenue?
Piramal Pharma reported revenue of INR 82.1 billion for FY2025 (ending March 2025). The CDMO segment contributed approximately INR 49 billion, critical care approximately INR 20 billion, and consumer healthcare approximately INR 13 billion. The company has been investing in capacity expansion at its CDMO facilities to capture growth in HPAPIs and antibody-drug conjugates.

What is Piramal Pharma Solutions?
Piramal Pharma Solutions is the company's CDMO business division, providing integrated contract development and manufacturing services to global pharmaceutical companies. It offers services across the drug development lifecycle, from API synthesis to commercial manufacturing, with expertise in HPAPIs, sterile injectables, and antibody-drug conjugates. The division operates facilities in India, the United States, the United Kingdom, Canada, and Germany.

Piramal Pharma's origins trace to 1988, when Ajay Piramal's Piramal Group acquired Nicholas Laboratories India Limited, a pharmaceutical company with operations in India. This acquisition marked the Piramal Group's entry into the pharmaceutical industry. At the time, the Piramal Group was a diversified conglomerate with interests in textiles, glass, and real estate, and the pharmaceutical acquisition represented a new direction.

In 1993, the group acquired Roche Products (India) Limited from Hoffmann-La Roche, which was later renamed Piramal Healthcare Limited. This acquisition added significant pharmaceutical manufacturing capabilities and gave the company a presence in the Indian formulations market. The Roche acquisition was part of a broader strategy of acquiring multinational pharmaceutical companies' Indian operations, a common pattern in the 1990s as foreign companies divested their Indian subsidiaries.

Throughout the late 1990s and early 2000s, Piramal Healthcare expanded its CDMO capabilities. The company acquired the Hoechst Research Centre in Mulund, Mumbai in 2000, adding research and development capacity. It built expertise in active pharmaceutical ingredient (API) manufacturing and drug formulation development, positioning itself as a contract manufacturer for global pharmaceutical companies.

A landmark strategic decision came in 2010, when Piramal Healthcare sold its domestic formulations business to Abbott Laboratories for approximately $3.72 billion. This was one of the largest pharmaceutical deals in Indian history. The sale transferred Piramal's branded generics portfolio, including products in cardiovascular, respiratory, and central nervous system therapeutic areas, to Abbott. The decision was controversial because it meant exiting a large and growing Indian pharmaceutical market, but it provided capital for the company to focus on higher-margin CDMO services, critical care generics, and consumer healthcare.

Following the Abbott sale, Piramal expanded its CDMO business through a series of acquisitions in regulated markets. In 2012, the company acquired Decision Point, a US-based pharmaceutical consulting firm, and Coldstream Laboratories, a US-based CDMO specializing in sterile injectables. Also in 2012, Piramal acquired Ash Stevens, a US-based API manufacturer specializing in highly potent active pharmaceutical ingredients (HPAPIs). In 2013, the company acquired Torcan Chemical, a Canadian API manufacturer.

These acquisitions gave Piramal Pharma a manufacturing footprint in North America and expertise in complex chemistry, including HPAPIs and controlled substances. This positioned the company as a niche CDMO capable of handling difficult manufacturing projects that larger competitors were less willing to take on.

In 2020, the Carlyle Group invested approximately $490 million in Piramal Pharma for approximately a 20% stake. This investment provided growth capital and represented an independent validation of the company's CDMO strategy. The Carlyle investment was structured through compulsorily convertible preference shares, which converted to equity during the 2022 demerger.

In October 2022, Piramal Enterprises Limited was restructured. The pharmaceutical and healthcare operations were demerged into Piramal Pharma Limited, and the financial services operations continued under Piramal Enterprises. Piramal Pharma was listed on the NSE and BSE on October 19, 2022. The demerger allowed the pharmaceutical business to be valued independently and gave investors direct exposure to its growth trajectory.

For FY2024 (ending March 2024), Piramal Pharma reported revenue of approximately INR 80 billion. For FY2025 (ending March 2025), revenue grew to INR 82.1 billion. The company has been investing in capacity expansion at its CDMO facilities, including a new HPAPI manufacturing unit at its Riverview, Michigan site and additional capacity at its Digwal, India facility.

In 2025 and 2026, the company continued to expand its CDMO capabilities, focusing on antibody-drug conjugates (ADCs) and other complex modalities. The company announced investments in peptide manufacturing capacity and expanded its analytical services portfolio. Piramal Pharma also received several regulatory approvals from the US FDA for its manufacturing facilities, reinforcing its position in the regulated markets CDMO segment.

Piramal Pharma publishes a sustainability report as part of its ESG disclosures. The company's sustainability strategy focuses on environmental compliance, waste reduction, and responsible manufacturing practices across its 17 facilities.

The company is not a Certified B Corporation. It does not have independently verified science-based targets for emissions reduction through the SBTi. The company reports Scope 1 and Scope 2 emissions in its sustainability disclosures but has not publicly committed to a net-zero target year.

As a pharmaceutical manufacturer, Piramal Pharma's environmental footprint includes solvent use, waste generation from chemical synthesis, and energy consumption at manufacturing facilities. The company has implemented solvent recovery programs and waste reduction initiatives at its Indian facilities. Its US and UK facilities are subject to local environmental regulations and have maintained compliance records.

The company's consumer healthcare products, including i-pill (emergency contraceptive), have contributed to public health access in India. i-pill is one of the most widely available emergency contraceptive brands in the country, sold at pharmacies without a prescription. The company has not faced significant controversy related to its consumer healthcare products.

As a pharmaceutical manufacturer operating in regulated markets, Piramal Pharma is subject to oversight by the US FDA, UK MHRA, European EMA, and India's CDSCO. The company's manufacturing facilities undergo routine inspections by these regulatory bodies. In recent years, the company has received FDA approvals for several of its facilities, including its Riverview, Michigan site and its Digwal, India site, without major adverse findings.

The 2010 sale of Piramal's domestic formulations business to Abbott for $3.72 billion was a controversial strategic decision within the Indian pharmaceutical industry. Critics argued that the sale represented a loss of Indian-owned pharmaceutical assets to a foreign company. Ajay Piramal defended the decision as a value-unlocking move that allowed the group to reinvest in higher-margin businesses. The proceeds were reinvested in CDMO capabilities, financial services, and other group businesses.

The company has not faced major product recalls, safety scandals, or regulatory enforcement actions in recent years. Its manufacturing facilities have maintained regulatory compliance with FDA, MHRA, and EMA standards. The company's handling of HPAPIs and controlled substances requires additional regulatory oversight, which it has managed without significant violations.